CERS 8-K SEC Filing Analysis

Latest settled — T+20d

CERS ▲ +4.41% at T+20d

LONG call ✓ call won +4.41% · α vs SPY -0.87% · entry $2.72 → $2.84

Next anchor: T+60d in 6w

Last close $2.56 (close Jun 12) · -5.88% from $2.72 entry

Entry anchored
Apr 30, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.34%

$2.72

settled 6w ago

T+5d

-4.04%

call -4.04% · α -6.39%

$2.61

settled 6w ago

T+20d

+4.41%

call +4.41% · α -0.87%

$2.84

settled 17d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Cerus Corp reported Q1 2026 product revenue of $53.7M (+24% YoY), beating consensus estimates, and narrowed its net loss to $1.6M from $7.7M a year ago. The company raised its full-year 2026 product revenue guidance to $227M-$231M (from $224M-$228M), driven by strong IFC demand and global platelet franchise growth.

Key Financial Metrics

Guidance

$227M-$231M

raised

Gross Margin

52%

Actionable Insight

The raised guidance and strong IFC growth signal accelerating commercial momentum. Watch for the Phase 3 RedeS readout and INT200 PMA submission as near-term catalysts. The CEO transition adds some uncertainty but appears orderly.

Key Facts

Q1 2026 product revenue $53.7M, up 24% YoY from $43.2M
Total revenue $59.9M, up 23% YoY from $48.9M
Net loss narrowed to $1.6M ($0.01/share) from $7.7M ($0.04/share) YoY
Non-GAAP adjusted EBITDA improved to $4.0M from $0.2M YoY
Full-year 2026 product revenue guidance raised to $227M-$231M (10-12% growth)
IFC demand up ~120% YoY; U.S. IFC sales $5.7M vs $3.0M
Signed 4-year supply agreement with French Blood Establishment (EFS)
CEO transition announced: Vivek Jayaraman to become CEO effective July 1, 2026

Financial Impact

Product revenue beat consensus by ~$2.5M (4.9%); guidance raised by $3M at midpoint

revenueepsebitdaguidance

Risk Factors

Product gross margin compressed to 52.0% from 58.8% due to tariffs, FX, and one-time benefits in prior year
Operating cash flow negative $3.0M in Q1 vs negative $0.8M a year ago
Debt of $84.8M ($65M term loan + $19.9M revolver) vs $80.4M cash; net debt position
CEO transition effective July 1 introduces execution risk

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

78% bullish (9 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-197129
Document: cers-20260430.htm	0001193125-26-197129
Document: 0001193125-26-197129-index-headers.html	0001193125-26-197129
Document: 0001193125-26-197129-index.html	0001193125-26-197129
Document: 0001193125-26-197129.txt	0001193125-26-197129
8-K Data (Synthetic)	0001193125-26-197129

6 reports for CERS

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CERS — sortable, filterable
	Type				Now
Apr 30, 2026 6w ago	8-K BULLISH ★ 7/10	$2.72 $2.84	▲ +4.41%	▼ −0.87%	$2.56 (−5.88%)
Apr 22, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$1.94 $2.70	▲ +39.18%	▲ +36.01%	$2.56 (+31.96%)
Apr 21, 2026 7w ago	8-K NEUTRAL ★ 3/10	$1.94 $2.70	▲ +39.18%	▲ +36.01%	$2.56 (+31.96%)
Mar 6, 2026 14w ago	Insider Cluster BEARISH ★ 6/10	$1.93 $1.85	▲ +4.15%	▲ +2.10%	$2.56 (−32.64%)
Mar 6, 2026 14w ago	Insider Cluster NEUTRAL ★ 3/10	$1.93 $1.85	▼ −4.15%	▼ −2.10%	$2.56 (+32.64%)
Mar 5, 2026 14w ago	Insider Cluster NEUTRAL ★ 4/10	$2.04 $1.86	▼ −8.82%	▼ −5.03%	$2.56 (+25.49%)

US Market Status

Market Closed — Opens in 3h 58m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access